Literature DB >> 7986216

Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis.

P Miossec1, P Chomarat, J Dechanet, J F Moreau, J P Roux, P Delmas, J Banchereau.   

Abstract

OBJECTIVE: To assess local bone resorption in the context of rheumatoid synovitis and its modulation by interleukin-4 (IL-4).
METHODS: We developed an ex vivo model of bone resorption using juxtaarticular samples of bone obtained during joint surgery. We studied the histomorphometric parameters of bone resorption and the regulation of the production of IL-6, leukemia inhibitory factor (LIF), and the collagen cross-link pyridinoline, which is released during bone resorption in vivo.
RESULTS: This was a sensitive and dynamic model of bone resorption. The bone samples produced high levels of pyridinoline and as much cytokine as synovium pieces obtained from the same joint. IL-4 induced a 70% reduction of IL-6 and LIF production by bone pieces and reduced pyridinoline levels. Histomorphometric studies performed on bone samples indicated a 35% increase in the mean total bone area after 7 days of treatment with IL-4. More importantly, with IL-4, osteoclasts were not detectable in the bone sections.
CONCLUSION: The inhibitory effect of IL-4 on bone resorption extends our knowledge of its antiinflammatory properties and suggests that the inflammatory cytokine imbalance in rheumatoid synovium also contributes to defects in bone resorption in RA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986216     DOI: 10.1002/art.1780371202

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

1.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

Authors:  A C Bendixen; N K Shevde; K M Dienger; T M Willson; C D Funk; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

2.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.

Authors:  Y Abu-Amer
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Contribution of Reduced Interleukin-10 Levels to the Pathogenesis of Osteomyelitis in Children with Sickle Cell Disease.

Authors:  Sameh Sarray; Wassim Y Almawi
Journal:  Clin Vaccine Immunol       Date:  2015-07-01

4.  Preservation of high-fat diet-induced femoral trabecular bone loss through genetic target of TNF-α.

Authors:  Kun Zhang; Chunyu Wang; Yaxi Chen; Xiao Ji; Xiang Chen; Li Tian; Xijie Yu
Journal:  Endocrine       Date:  2015-02-21       Impact factor: 3.633

5.  Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium.

Authors:  Allison J Rao; Christophe Nich; Lakshmi S Dhulipala; Emmanuel Gibon; Roberto Valladares; Stefan Zwingenberger; R Lane Smith; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2012-12-05       Impact factor: 4.396

6.  In vitro differentiation of peripheral blood T cells towards a type 2 phenotype is impaired in rheumatoid arthritis (RA).

Authors:  S Asselin; H Conjeaud; D Fradelizi; M Breban
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 7.  The role of the T cell in autoimmune inflammation.

Authors:  Alla Skapenko; Jan Leipe; Peter E Lipsky; Hendrik Schulze-Koops
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

Review 8.  [Postoperative and bacterial osteitis. New possibilities for therapy].

Authors:  V Heppert; U Glatzel; A Wentzensen
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

9.  IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism.

Authors:  P P C Souza; A B Brechter; R I Reis; C A S Costa; P Lundberg; U H Lerner
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Influence of interleukin 1alpha (IL-1alpha), IL-4, and IL-6 polymorphisms on genetic susceptibility to chronic osteomyelitis.

Authors:  Aspasia Tsezou; Lazaros Poultsides; Fotini Kostopoulou; Elias Zintzaras; Maria Satra; Sofia Kitsiou-Tzeli; Konstantinos N Malizos
Journal:  Clin Vaccine Immunol       Date:  2008-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.